BioCentury
ARTICLE | Company News

Novozymes, sanofi-aventis deal

January 5, 2009 8:00 AM UTC

sanofi-aventis received exclusive, worldwide rights from Novozymes to NZ2114 to treat infections caused by Gram-positive bacteria. The variant of plectasin, which interferes with cell wall biosynthesi...